February 6, 2020 / 10:27 PM / 19 days ago

BRIEF-Zogenix Announces Positive Top-Line Results From Global Pivotal Phase 3 Trial Of Fintepla

Feb 6 (Reuters) - Zogenix Inc:

* ZOGENIX ANNOUNCES POSITIVE TOP-LINE RESULTS FROM GLOBAL PIVOTAL PHASE 3 TRIAL OF FINTEPLA® FOR THE TREATMENT OF LENNOX-GASTAUT SYNDROME

* ZOGENIX INC - PRIMARY ENDPOINT ACHIEVED FROM GLOBAL PIVOTAL PHASE 3 TRIAL OF FINTEPLA

* ZOGENIX INC - FINTEPLA ALSO DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT ON MULTIPLE SECONDARY ENDPOINTS

* ZOGENIX - MEDIAN % FALL IN MONTHLY DROP SEIZURES BETWEEN BASELINE, TREATMENT PERIOD FOR LOWER DOSE OF FINTEPLA DID NOT REACH STATISTICAL SIGNIFICANCE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below